Who Paid My Doc
Kirtan Koticha
Hematology & Oncology Shreveport, LA Medical Doctor
NPI 1528279965 CMS profile 1303670
1455 E Bert Koun Loop # 101, Shreveport, LA 71105
General payments
$45,087
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$72,172
Through program year 2025, Kirtan Koticha of Shreveport, LA is reported in the CMS Open Payments database as having received $45,087 across 1,309 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $72,172 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 88th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,435 | 215 | |
| 2024 | General | $4,214 | 189 | |
| 2023 | General | $21,110 | 236 | |
| 2022 | General | $3,981 | 205 | |
| 2021 | General | $1,872 | 96 | |
| 2020 | General | $1,809 | 126 | |
| 2019 | General | $3,665 | 242 |
Beside peers
- Kirtan Koticha
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Kirtan Koticha were reported at $8,435. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Kirtan Koticha | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,665 | $529 | $121–$2,516 | $163 |
| 2020 | $1,809 | $339 | $82–$2,213 | $114 |
| 2021 | $1,872 | $263 | $49–$1,965 | $132 |
| 2022 | $3,981 | $416 | $103–$2,395 | $149 |
| 2023 | $21,110 | $542 | $125–$2,646 | $160 |
| 2024 | $4,214 | $692 | $141–$3,008 | $164 |
| 2025 | $8,435 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 111 drugsPart D claims
5,529
Drug cost
$26,260,530
Branded share of claims
63.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | Brand | 178 | $2,886,783 | |
| Revlimid Lenalidomide | Brand | 72 | $1,636,394 | |
| Jakafi Ruxolitinib Phosphate | Brand | 77 | $1,267,164 | |
| Lenalidomide | Generic | 75 | $1,151,015 | |
| Procrit Epoetin Alfa | Brand | 292 | $1,150,510 | |
| Xtandi Enzalutamide | Brand | 77 | $1,065,688 | |
| Lumakras Sotorasib | Brand | 45 | $927,028 | |
| Brukinsa Zanubrutinib | Brand | 59 | $859,632 | |
| Nubeqa Darolutamide | Brand | 66 | $851,064 | |
| Fruzaqla Fruquintinib | Brand | 33 | $810,039 |
The 10 drugs with the highest cost, of 111 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 174 billing codesPaid by Medicare
$9,405,318
Medicare patients
1,182
Services billed
398,318
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 60% | |
| Osteoporosis | 37% | |
| Diabetes | 35% | |
| Ischemic heart disease | 31% | |
| Chronic kidney disease | 30% | |
| Cancer | 30% | |
| COPD | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 29 | 47,000 | $2,100,176 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 | Office | 16 | 17,640 | $681,329 |
| Injection, denosumab, 1 mg J0897 | Office | 197 | 30,840 | $628,969 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 179 | 24,700 | $389,168 |
| Injection, rituximab, 10 mg J9312 | Office | 11 | 3,360 | $206,368 |
| Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg Q5130 | Office | 17 | 732 | $114,406 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 21 | 3,930 | $96,677 |
| Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg Q5108 | Office | 13 | 636 | $74,493 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 11 | 6,550 | $59,783 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 28 | 7,240 | $46,288 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 68 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ENHERTU |
|
$168 | — | — |
| REBLOZYL |
|
$154 | 53 | — |
| KEYTRUDA |
|
$141 | 68 | — |
| TECENTRIQ |
|
$130 | 45 | — |
| Lenvima |
|
$123 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 68 with PatronRecords
1,309 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Louisiana
Hana Safah
Hematology & Oncology · Baton Rouge, LA
Pedro Barata
Hematology & Oncology · New Orleans, LA
Maissaa Janbain
Hematology & Oncology · New Orleans, LA
Nakhle Saba
Hematology & Oncology · Baton Rouge, LA
Marc Matrana
Hematology & Oncology · New Orleans, LA
Prakash Peddi
Hematology & Oncology · Shreveport, LA
Related records
Hematology & Oncology in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.